A detailed history of Core Cap Advisors, LLC transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Core Cap Advisors, LLC holds 290 shares of TSHA stock, worth $785. This represents 0.0% of its overall portfolio holdings.

Number of Shares
290
Previous 380 23.68%
Holding current value
$785
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 09, 2025

SELL
$1.39 - $2.05 $125 - $184
-90 Reduced 23.68%
290 $0
Q4 2024

Feb 14, 2025

BUY
$1.27 - $3.24 $482 - $1,231
380 New
380 $0

Others Institutions Holding TSHA

About Taysha Gene Therapies, Inc.


  • Ticker TSHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,359,500
  • Market Cap $131M
  • Description
  • Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...
More about TSHA
Track This Portfolio

Track Core Cap Advisors, LLC Portfolio

Follow Core Cap Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Core Cap Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Core Cap Advisors, LLC with notifications on news.